Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
44 NC counties are under alert, including Wake, Cumberland, Durham, Johnston, and Wayne counties.
Program
On FOX 50 at 10: Rain and flooding persisting tonight. WRAL has crews surveying the area and has the spots youâll want to avoid
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gain Therapeutics Inc
(NQ:
GANX
)
1.380
+0.020 (+1.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gain Therapeutics Inc
< Previous
1
2
Next >
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
September 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
September 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Via
Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,...
Via
TheNewswire.com
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
August 28, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 10, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
August 07, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
July 31, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
May 03, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
March 29, 2023
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 23, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
March 22, 2023
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
March 21, 2023
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
February 27, 2023
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
February 02, 2023
Gain to present new preclinical data on its lead programs in GBA1-related diseases
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
January 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 10, 2022
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Strong Cash Position of $43.2 Million Provides Runway into 2nd half of 2023 to Advance the Company’s Programs for Gain Therapeutics, Inc. (NASDAQ: GANX)
August 23, 2021
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
This NASDAQ is Unlocking New Treatments for Neurodegenerative and Lysosomal Storage Diseases: Gain Therapeutics, Inc. (NASDAQ: GANX)
August 02, 2021
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.